More than 300,000 patients have used Nevisense melanoma detection tests, according to Nevisense Maker SciBase.
Nevisense uses non-invasive electrical impedance spectroscopy to measure how electricity flows through skin at different depths. Point-of-care results enable more efficient biopsy management decisions while ensuring that high-risk cases receive timely attention.
“We are excited by this milestone, which we believe is a testament to our shared desire with the melanoma healthcare community to improve the lives of patients,” says Pia Renaudin, CEO of SciBase, in a news release. “With every Nevisense test, we aim to enable clinicians to make more informed, more precise early-detection decisions that can significantly improve patient outcomes.”
